Posted Jun. 30, 2010 at 12:31 p.m.

Premium Lock Generic versions of Roundup cut into Monsanto profits

Published: 2010-06-30 12:31:06
Updated: 2010-06-30 12:31:06

Print this blog post
Monsanto Monsanto

ST. LOUIS - Monsanto Co. (NYSE: MON), the world's biggest seed maker, said Wednesday its fiscal third quarter net income dropped 45 percent on declining herbicide sales.

Monsanto said cheaper, generic versions of its Roundup herbicide continued to eat into its results.

The company has a significant operation in Research Triangle Park, N.C., and {{a href="blogpost-1}}is establishing a presence{{/a}} at the North Carolina Research Campus in Kannapolis.

As Roundup sales have flagged, Monsanto has accelerated its longterm strategy to shift its business from chemcials and herbicides to genetically altered seeds. But the the declines in Roundup has been surprisingly steep, the company has said, as generic competition from China has expanded.

The St. Louis company said its net income dropped to $384 million, or 70 cents a share in the quarter ended May 31, down from $694 million, or $1.25 a share, a year ago.

Analysts had been looking for a profit of 79 cents per share, according to a survey by Thomson Reuters.

Revenue fell to $2.96 billion from $3.16 billion a year ago. Analysts expected revenue of $3.17 billion.

Sales in Monsanto's agricultural productivity unit, which includes Roundup, fell 34 percent to $600 million in the quarter. Seeds and genomic sales, by contrast, rose 5 percent to $2.36 from the same period last year.

Corn seed sales remained flat at $1 billion dollars, while soybean sales rose 2 percent to $549 million.

Get the latest news alerts: Follow LTW at Twitter.
 

...Copyright 2013 WRAL Tech Wire. All rights reserved.

Please log in to view WRALTechWire Insider content


To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.

Editor's Blog

Editor's Blog

The latest blog posts from our WRAL Tech Wire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Vivek Wadhwa
Commentary
Jim Roberts
Entrepreneurship
Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Scroll